LexaGene Holdings Inc. reported earnings results for the third quarter and nine months ended November 30, 2022. For the third quarter, the company reported sales was USD 0.042912 million compared to USD 0.048309 million a year ago. Net loss was USD 1.68 million compared to USD 2.69 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.02 a year ago.
For the nine months, sales was USD 0.117886 million compared to USD 0.088934 million a year ago. Net loss was USD 5.89 million compared to USD 8.31 million a year ago. Basic loss per share from continuing operations was USD 0.04 compared to USD 0.07 a year ago.